We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A multi-center, prospective, open-label, single arm ...

Acne vulgaris affects over 650 million people worldwide, especially teenagers. About 85% of teens develop acne, and many face ...

The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020. The first-in-class ...

Other therapies may be necessary to remove cysts and fistulae and/ or to correct acne scars. Among them are intralesional steroid injections for cysts, surgery for drainage and excision of pustules ...

LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonist users were 1.36 times more likely ...

More than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” ...

Subject of the leading article in last week’s American Medical Association Journal was acne vulgaris—the blackheads and pimples of adolescence. Dr. Jeffrey Charles Michael, Houston acne specialist who ...

Acne vulgaris remains one of the most pervasive inflammatory skin conditions worldwide, affecting not only adolescents but also adults and contributing to significant psychosocial burden. The ...

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...